Şunu aradınız:: rmv (Slovakça - İngilizce)

najčastejšie a jednotne uvádzané nežiaduce účinky spojené s liečbou kineretom boli rmv.
the most common and consistently reported treatment-related adverse reactions associated with kineret were isrs.

väčšina (95%) hlásených rmv bola mierneho až stredného charakteru.
the majority (95%) of isrs were reported as mild to moderate.

najčastejšie a jednotne uvádzané nežiaduce reakcie spojené s liečbou kineretom u pacientov s ra boli rmv.
in ra patients the most common and consistently reported treatment-related adverse reactions associated with kineret were isrs.

rmv sa obvykle vyskytujú počas 2 týždňov liečby a vymiznú počas 4 - 6 týždňov.
isrs typically appear within 2 weeks of therapy and disappear within 4-6 weeks.

vývoj rmv u pacientov, ktorí nemali predchádzajúce skúsenosti s rmv, bol menej častý po prvom mesiaci terapie.
the development of isrs in patients who had not previously experienced isrs was uncommon after the first month of therapy.

pri dávke 100 mg/deň sa rmv vyvinula u 71 % pacientov s ra v porovnaní s 28 % pacientov dostávajúcich placebo.
at a dose of 100 mg/day, 71% of ra patients developed an isr compared to 28% of the placebo treated patients.